These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23138923)

  • 21. Risk assessment of endocrine active chemicals: identifying chemicals of regulatory concern.
    Bars R; Fegert I; Gross M; Lewis D; Weltje L; Weyers A; Wheeler JR; Galay-Burgos M
    Regul Toxicol Pharmacol; 2012 Oct; 64(1):143-54. PubMed ID: 22735369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developmental and reproductive toxicology studies in nonhuman primates.
    Chellman GJ; Bussiere JL; Makori N; Martin PL; Ooshima Y; Weinbauer GF
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):446-62. PubMed ID: 20025046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. International Conference on Harmonisation; guidance on M4 common technical document; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Oct; 66(200):52634-7. PubMed ID: 12358037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of in vitro data in risk assessment.
    Bernauer U; Oberemm A; Madle S; Gundert-Remy U
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):176-81. PubMed ID: 15733212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A category approach for reproductive effects of phthalates.
    Fabjan E; Hulzebos E; Mennes W; Piersma AH
    Crit Rev Toxicol; 2006 Oct; 36(9):695-726. PubMed ID: 17050082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of the toxicology of acrylamide.
    Exon JH
    J Toxicol Environ Health B Crit Rev; 2006; 9(5):397-412. PubMed ID: 17492525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ReProTect Feasibility Study, a novel comprehensive in vitro approach to detect reproductive toxicants.
    Schenk B; Weimer M; Bremer S; van der Burg B; Cortvrindt R; Freyberger A; Lazzari G; Pellizzer C; Piersma A; Schäfer WR; Seiler A; Witters H; Schwarz M
    Reprod Toxicol; 2010 Aug; 30(1):200-18. PubMed ID: 20493943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of global regulatory toxicology requirements for vaccines and adjuvants.
    Sun Y; Gruber M; Matsumoto M
    J Pharmacol Toxicol Methods; 2012 Mar; 65(2):49-57. PubMed ID: 22326278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of genotoxic impurities in pharmaceutical development.
    Bercu JP; Dobo KL; Gocke E; McGovern TJ
    Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ICH S9: Developing anticancer drugs, one year later.
    Ponce R
    Toxicol Pathol; 2011 Oct; 39(6):913-5. PubMed ID: 21859887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern.
    Laufersweiler MC; Gadagbui B; Baskerville-Abraham IM; Maier A; Willis A; Scialli AR; Carr GJ; Felter SP; Blackburn K; Daston G
    Regul Toxicol Pharmacol; 2012 Feb; 62(1):160-82. PubMed ID: 22019814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction to special issue on developmental and reproductive toxicology in China.
    Daston GP
    Birth Defects Res B Dev Reprod Toxicol; 2010 Feb; 89(1):1. PubMed ID: 20166228
    [No Abstract]   [Full Text] [Related]  

  • 35. Current and future needs for developmental toxicity testing.
    Makris SL; Kim JH; Ellis A; Faber W; Harrouk W; Lewis JM; Paule MG; Seed J; Tassinari M; Tyl R
    Birth Defects Res B Dev Reprod Toxicol; 2011 Oct; 92(5):384-94. PubMed ID: 21922641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone Therapeutics: Safety Considerations, Session Summary.
    Jerome CP; Boyce R
    Toxicol Pathol; 2017 Oct; 45(7):855-858. PubMed ID: 29108483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The expanding role of predictive toxicology: an update on the (Q)SAR models for mutagens and carcinogens.
    Benigni R; Netzeva TI; Benfenati E; Bossa C; Franke R; Helma C; Hulzebos E; Marchant C; Richard A; Woo YT; Yang C
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2007; 25(1):53-97. PubMed ID: 17365342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Providing toxicokinetic support for reproductive toxicology studies in pharmaceutical development.
    Schwartz S
    Arch Toxicol; 2001 Sep; 75(7):381-7. PubMed ID: 11693177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of pharmacokinetics as an interpretive and predictive tool in chemical toxicology testing and risk assessment: a position paper on the appropriate use of pharmacokinetics in chemical toxicology.
    Frantz SW; Beatty PW; English JC; Hundley SG; Wilson AG
    Regul Toxicol Pharmacol; 1994 Jun; 19(3):317-37. PubMed ID: 8090955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent developments in regulatory requirements for developmental toxicology.
    Kimmel CA; Makris SL
    Toxicol Lett; 2001 Mar; 120(1-3):73-82. PubMed ID: 11323164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.